Siplizumab: Phase I/II

BTRN said that in a U.S. Phase I trial of MEDI-507 as a

Read the full 136 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE